On August 24, 2026, Brivaracetam — UCB (Epilepsy) reached its Phase 3 readout. The result was a neutral outcome, and the stock moved -0.6% in the window around the event. It had already run -7.0% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$129.23
1d before
$128.50
Event day
$130.83
1d after
$125.29
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (+0.0% expected); the stock actually moved -0.6%. Model confidence at the time: 95%.
See the full scored track recordPre-catalyst setup
-7.0%
30-day run-up
5312%
30-day volatility
0.9×
volume spike